Research programme: autoimmune disorder therapies - VLST Corporation
Latest Information Update: 25 Jun 2014
At a glance
- Originator VLST Corporation
- Mechanism of Action Cytokine inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 25 Jun 2014 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 25 Jun 2014 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 18 Aug 2008 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)